Instem (INS)

 

INS Share PerformanceMore

52 week high235.00 20/01/17
52 week low140.00 07/12/17
52 week change -53.00 (-22.94%)
4 week volume322,857 25/12/17

Media for (INS)

Presenter: Phil Reason, CEO
04/02/2015

Latest NewsMore

Instem wins contract worth over £1.7m

Instem has won a new two-year SEND (standard for the exchange of nonclinical data) outsourced services contract by a to...

Contract Win

RNS Number: 9455B Instem plc 16 January 2018 Instem plc ("Instem", the "Company" or the "Group") SEND outsourced services contract win Top five global nonclinical CRO outsources all SEND data set generation to Instem Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, is pleased to announce the award of a new two-yea...

Trading Statement

RNS Number: 9452B Instem plc 16 January 2018 Instem plc ("Instem", the "Company" or the "Group") Trading Statement FY17 results in-line with market expectations with positive outlook Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces a trading update for the year ended 31 December 2017. Financial Highlights F...

Holding(s) in Company

RNS Number: 8269S Instem plc 05 October 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: INSTEM PLC 1b. Please ind...

Issue of Equity & Total Voting Rights

RNS Number: 2685S Instem plc 29 September 2017 Instem plc (" Instem " or the " Company ") Issue of Equity and Total Voting Rights Instem plc (AIM: INS), a leading provider of IT solutions and services to the global life sciences market, announces that, following the exercise of vested EMI share options, 20,000 ordinary shares of 10p each in the Company (" Ordinar...

Instem adjusted pre-tax profits fall

Instem's total revenues increased 13% to 10.3m in the six months to the end of June with recurring revenues up 23% at 6.5m...

Half-year Report

RNS Number: 7698R Instem plc 26 September 2017 Instem plc ("Instem", the "Company" or the "Group") Half Yearly Report Instem plc (AIM: INS.L), a leading provider of IT solutions to the global life sciences market, announces its unaudited half year results for the six months ended 30 June 2017. Financial Highlights Total revenues increased 13% to 10.3m (H1 2016: 9...

Holding(s) in Company

RNS Number: 4983R Instem plc 21 September 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: INSTEM Plc 1b. Please in...

Fundamental DataMore

P/E ratio25.797
EPS6.9
Dividend yield0 %

Latest discussion posts More

  • Re: Artemis Aim VCT (Financial Report 30/9/1...

    They have been active in Japan recently. Patience certainly needed.
    19-Dec-2017
    Carefully Does It
  • Artemis Aim VCT (Financial Report 30/9/17)

    Artemis Aim VCT (Annual Financial Report for the year ended 30 September 2017) :- Instem plc too has had a rocky twelve months. The Food and Drug Administration ("FDA") ...
    19-Dec-2017
    Red Ninja
  • NEW ARTICLE: Instem worth 24% more

    "I first spoke to LSE:INS:Instem early last year. The AIM-listed company was worth A#22 million and demand for its software, which helps drug companies develop commercial drugs ...
    19-Sep-2016
    II Editor

Users' HoldingsMore

Users who hold Instem also hold..

Codes & Symbols

ISINGB00B3TQCK30
SymbolsINS, LSE:INS, INS.L, INS:LN, LON:INS, XLON:INS

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account